The earlier the better? Apalutamide for non-metastatic castration resistant prostate cancer

The earlier the better? Apalutamide for non-metastatic castration resistant prostate cancer

Bibliographic Details
Main Authors:	Maria De Santis, Thomas Steuber
Format:	Article
Language:	English
Published:	Elsevier 2019-04-01
Series:	ESMO Open
Online Access:	https://esmoopen.bmj.com/content/4/2/e000484.full

Similar Items

Apalutamide: Emerging Therapy for Non-Metastatic Castration-Resistant Prostate Cancer
by: Nora A. Alkhudair
Published: (2019-03-01)

Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
by: Gul A, et al.
Published: (2019-08-01)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
by: Saizo Fujmoto, et al.
Published: (2023-02-01)

The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
by: Sambit Tripathy
Published: (2021-01-01)

Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials
by: Vadim S. Koshkin, et al.
Published: (2018-12-01)

Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial
by: Byung Ha Chung, et al.
Published: (2023-01-01)

Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States
by: Arif Hussain, et al.
Published: (2022-03-01)

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
by: Carlo Cattrini, et al.
Published: (2022-03-01)

Efficacy and safety of apalutamide in patients with metastatic castration-resistant prostate cancer (GENESIS): protocol for a multicentre, open-label, single-arm clinical trial
by: Masato Fujisawa, et al.
Published: (2023-03-01)

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
by: Gustavo Werutsky, et al.
Published: (2019-05-01)

Interstitial lung disease induced by apalutamide therapy for castration‐resistant prostate cancer: A report of a rare case
by: Fumiaki Kirishima, et al.
Published: (2022-05-01)

Apalutamide-Induced Toxic Epidermal Necrolysis in a Caucasian Patient with Metastatic Castration-Sensitive Prostate Cancer: A Case Report and Review of the Literature
by: Calvin R. Flynn, et al.
Published: (2023-08-01)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
by: Harkirat Singh Talwar
Published: (2021-01-01)

Editorial Comment to Interstitial lung disease induced by apalutamide therapy for castration‐resistant prostate cancer: A report of a rare case
by: Takeshi Yuasa
Published: (2022-05-01)

Lower baseline testosterone level is related to earlier development of castration resistance in metastatic prostate cancer: a multi-center cohort study
by: Ho Ming Chris Wong, et al.
Published: (2024-02-01)

Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate Cancer
by: Stephanie Gleicher, et al.
Published: (2021-05-01)

The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer
by: Joelle El-Amm, et al.
Published: (2019-02-01)

Physician preferences for non-metastatic castration-resistant prostate cancer treatment
by: Sandy Srinivas, et al.
Published: (2020-06-01)

Recent developments in the treatment of non-metastatic castration resistant prostate cancer
by: John Esther, et al.
Published: (2020-01-01)

Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer
by: Takashi Ueda, et al.
Published: (2024-01-01)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
by: Lixin Mai, et al.
Published: (2020-12-01)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
by: Goran Bencina, et al.
Published: (2023-06-01)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
by: Rodriguez-Vida A, et al.
Published: (2015-06-01)

PSMA theragnostics for metastatic castration resistant prostate cancer
by: Hong Song, et al.
Published: (2022-08-01)

Radium-223 in metastatic castration resistant prostate cancer
by: Winston Vuong, et al.
Published: (2014-06-01)

Treatment sequencing in metastatic castrate-resistant prostate cancer
by: Oliver Sartor, et al.
Published: (2014-06-01)

Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
by: Peter Arnold, et al.
Published: (2021-11-01)

Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer
by: İlkay Gültürk, et al.
Published: (2022-11-01)

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
by: Vincenza Conteduca, et al.
Published: (2021-01-01)

Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial
by: Byung Ha Chung, et al.
Published: (2022-01-01)

Prognostic significance of time to castration resistance in patients with metastatic castration-sensitive prostate cancer
by: Y. Matsushita, et al.
Published: (2020-07-01)

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
by: Wout Devlies, et al.
Published: (2020-11-01)

Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
by: Dhruv Bansal, et al.
Published: (2021-01-01)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
by: Joelle El-Amm, et al.
Published: (2013-08-01)

Denosumab-induced hypocalcaemia in metastatic castrate-resistant prostate cancer
by: Florence Gunawan, et al.
Published: (2019-12-01)

Editorial: Metastatic Castration Resistant Prostate Cancer: Prognosis and Treatment
by: Sakthivel Muniyan, et al.
Published: (2022-05-01)

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer
by: Joelle El-Amm, et al.
Published: (2016-03-01)

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer
by: Joelle El-Amm, et al.
Published: (2016-01-01)

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
by: Cedric Pobel, et al.
Published: (2021-09-01)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
by: Joelle El-Amm, et al.
Published: (2013-01-01)